Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $78
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and raises the price target from $50 to $78.
Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and raises the price target from $50 to $78.